Rhemacell 2G

A  THERAPEUTIC STEP TOWARDS HEALTH

OSTEOARTICULAR AND COLLAGEN ENZYME THERAPY

The latest and most effective treatment to combat rheumatoid arthritis, osteoarticular disorders, and connective tissue diseases, Rhemacell’s deep therapeutic action allows the patient to recover mobility, freedom of action and movement, without the deep pain which the ailment causes.   

Rhemacell is a collagen and connective tissue damage regulator.  Rhemacell includes the enzymes sulfurylase and choline acetylase, which contribute to restoring the functions lost by damaged connective tissues and toxin-contaminated collagen. Its use is indicated for treating:  arthritis, osteoarthritis, gout, herpes, neuralgia, neuritis, and lupus erythematosus.

Deep therapeutic action in cases of osteoarticular and connective tissue diseases. 

• Second-line treatment for rheumatoid arthritis, arthrosis, gout, neuritis, neuralgia, neurodermatitis, scleroderma, mixed connective tissue disease, and herpes.  
• Inhibits the Cyclooxygenase (COX) enzyme. Deep-acting treatment with progressive response.  
• No side effects.
• Maximum therapeutic safety and effectiveness.
• Flexible dosage: Available in two forms: injectable and oral, for ease of compliance.

Rhemacell is the only enzyme product, worldwide, which controls and detains the progress of osteoarticular and connective tissue diseases.

What are the most common symptoms of these diseases?
-Progressive joint pain.
-Sensitivity in joints.
-Pain in small joints of hand.
-Stiffness upon rising.
-Early evening fatigue.
-Low-grade fever.

What can be done to prevent these diseases?
Mainly, go to the doctor for a general check-up. In addition to a healthful diet which includes fruits and vegetables, the following should be taken as preventative measures:
-Moderate exercise.
-Periodic medical evaluations.

What can be done to cure these diseases?
Treatments differ according to the medical diagnosis.

What can be expected from this treatment?
Being natural products, the positive effects are progressive. Generally, an improvement is noted as of the first month.

What is its formula and what side effects does it have?
Rhemacell is composed of enzymes of plant origin which act directly on the metabolism (organisation) of the osteoarticular system, normalising its functions. Rhemacell does not interact with any other drug. It does not produce side effects, wherefore its use has no limitations or contraindications.

What does one feel when using Rhemacell?
Improvement is slow and progressive, but steady. We have to understand that these diseases tend to be chronic and that what one suffers—many times for years—is not going to be cured in a short time.  This non-invasive treatment requires time and consistency to achieve a significant improvement.

How long before effects are noted?
Since these diseases tend to be chronic, one can expect to start feeling an improvement after 30 or 45 days. Consistency in administering the treatment will allow a more pronounced improvement and will detain the progress of the disease.

What benefits are obtained?
In the short term:

• Diminished joint pain.
• Diminished pain in hands.
• Diminished stiffness upon rising.
• Diminished general malaise.

In the long term:

• A final cure can be obtained, which should be maintained through periodic medical evaluations.

CLINICAL INFORMATION AND PHARMACOLOGY

Composition
Sulfurylase
ATP: adenosine triphosphate
Sulfokinase
Phosphoadenyl sulfate
Chondroitin 4-sulphotransferase
Choline acetylase
Acetyl coenzyme A. Choline or acetyl transferase
Triethanolamine salicylate, 15 mg
Enzyme Nomenclature, 1992 IUBMB

Mechanism of Action:
The enzymes contained in Rhemacell trigger mechanisms which first detain the invasive action of immunocomplex pathogens, to initiate the disintegration thereof. They simply inhibit both cyclooxygenase and lipooxygenase, aggressive indicators of osteoarticular inflammatory processes.  

Pharmacokinetics:
The oral form is released in the intestinal tract. Its main active ingredients are absorbed into the bloodstream by active transport through the chyliferous membranes. Between 20 and 60% of the dose administered is reabsorbed as biologically intact molecules, which are then distributed systemically, attaining their maximum concentration 6 hours later, and maintaining peak strength for 24 hours. The enzymes absorbed are metabolised hepatically and are eliminated through faecal and urinary excretion.

In the case of the injectable form, the active substances are absorbed quickly into the bloodstream. A significant part of the dosage, between 20 and 60% of the administered dose, is reabsorbed as biologically intact molecules; 4 to 6 hours later, maximum concentrations have been found in the plasma, which tend to last approximately 24 hours. After absorption, the enzymes are distributed systemically, acting especially at the site where a disease produced by deficiency of the same is located.  This spot-targeting is based on the interaction with alpha-2 macroglobulin, a substance produced by activated immunological cells (macrophages/monocytes). The enzymes absorbed are eliminated by cells of the mononuclear phagocytic system, subsequently at the level of the liver, and ultimately through faecal excretion.

Indications and Dosage:
Hereunder we provide some therapeutic recommendations by way of example, which are based on vast clinical experience in the following areas of specialisation. However, it is up to the treating physician’s discretion to decide which dosages and therapeutic treatment are to be used, according to each specific case.
The clinical experience which this research has yielded supports the combined use thereof with other medications, since the coadjutant and boosting actions prove the preventative efficacy of Rhemacell.

 

Indications and Dosage by Specialisation, Dose, Frequency and Administration of the Treatment.

Rheumatology, Internal Medicine, General Medicine:
Rheumatism: The initial recommended dosage is to inject one (1) ampoule daily for 90 consecutive days, for a total of 90 injections. The injectable treatment should be administered together with 4 tablets twice a day (4 b.i.d.), morning and evening, before meals, taken on a daily basis. After completion of the 3-month initial treatment, it is recommended to continue with the treatment by injecting one (1) ampoule of Rhemacell every other day for three months, for a total of 45 injections of Rhemacell, together with 2 tablets twice a day (2 b.i.d.), morning and evening, before meals, taken on a daily basis. Patient should be evaluated monthly to ascertain whether to continue or discontinue treatment, as per physician’s discretion.   
Results: Once the first 4 weeks of treatment have elapsed, an improvement in the patient’s symptoms should be felt and be noted; its best effect will be noted mainly in joint movement, followed by improvement in inflammation levels and, lastly, decreased pain in the most critical areas.

Arthritis: The initial recommended dosage is to inject one (1) ampoule daily for 90 consecutive days, for a total of 90 injections. The injectable form should be administered together with 4 tablets twice a day (4 b.i.d.), morning and evening, before meals, taken on a daily basis. After completion of the 3-month initial treatment, it is recommended to continue with the treatment by injecting one (1) ampoule of Rhemacell every other day for three months, for a total of 45 injections of Rhemacell, together with 2 tablets twice a day (2 b.i.d.), morning and evening, before meals, taken on a daily basis. Patient should be evaluated monthly to ascertain whether to continue or discontinue treatment, as per physician’s discretion.  
Results: Once the first 4 weeks of treatment have elapsed, an improvement in the patient’s symptoms should be felt and noted; improvement will be noted mainly in the recovery in the medium term of small and large joints.

Arthrosis: The initial recommended dosage is to inject one (1) ampoule daily for 90 consecutive days, for a total of 90 injections. The injectable form should be administered together with 4 tablets twice a day (4 b.i.d.), morning and evening, before meals, taken on a daily basis. After completion of the 3-month initial treatment, it is recommended to continue with the treatment by injecting one (1) ampoule of Rhemacell every other day for three months, for a total of 45 injections of Rhemacell, together with 2 tablets twice a day (2 b.i.d.), morning and evening, before meals, taken on a daily basis. Patient should be evaluated monthly to ascertain whether to continue or discontinue treatment, as per physician’s discretion.
Results: Once the first 4 weeks of treatment have elapsed, an improvement in the patient’s symptoms should be noted, provided that the patient strictly follows the primary therapy and the treating physician’s recommendations.

Ischialgia: The initial recommended dosage is to inject one (1) ampoule of Rhemacell every other day for 60 days, for a total of 30 injections, together with 2 tablets twice a day (2 b.i.d.), morning and evening, taken on a daily basis before meals. Patient should be evaluated monthly to ascertain whether to continue or discontinue treatment, as per physician’s discretion.
Results: Once the first 2 to 3 weeks of treatment have elapsed, an improvement in the patient’s symptoms, and even a reduction in pain, should be noted, provided that the patient strictly follows the primary therapy and the treating physician’s recommendations.

Neuritis in General: The initial dosage for these cases is to take 4 tablets twice a day (4 b.i.d.), morning and evening, before meals, for a period of 30 consecutive days. Patient should be evaluated monthly and the dose should be decreased to 2 tablets daily or treatment should be discontinued, as per physician’s discretion.
Results: Once the first stages of the treatment have elapsed, an improvement in symptoms should be noted.

Rheumatic Ophthalmopathy: The initial dosage for these cases is 2 tablets twice a day (2 b.i.d.), morning and evening, before meals, for a period of 30 consecutive days. Patient should be evaluated monthly
Results: Once the first stages of the treatment have elapsed, a substantial improvement in symptoms should be noted.

Analysis:
The clinical effect obtained with Rhemacell is produced by means of the action of choline acetylase-type enzymes, through restoration of collagen function and detoxification. This implies that these enzymes have a therapeutic effect on collagen degeneration and diseases which fall under the term “Rheumatism.”  

Contraindications: As a product made from natural enzymes, it has no contraindications; therefore, it is compatible with any other medical treatment.

Side Effects: If, together with enzymatic preparations, other medications are administered, the latter have no effect on the enzymes injected or administered orally; however, substances such as neuroleptic agents, tranquilisers, sedatives, barbiturates, steroids and oestrogen, which suppress metabolic cycles, decrease the dynamic drug effect of the enzymes. Therefore, every effort should be made to avoid the simultaneous prescription of such substances.

Administration: Rhemacell should be injected slowly IM, in a vein, or directly in the joints. It is recommended that it not be administered after ingesting food. Preferably, one should wait 2 hours before administering it. Up to 5 injections may be administered in a single day with no contraindications. The injection does not cause pain or a burning sensation.


  

SUMMARY OF CLINICAL STUDY:
Usefulness of sulfurylase, sulfokinase and choline acetylase in the synthesis of intra-articular mucopolysaccharides in patients with rheumatoid arthritis.
Nickmann, Harry, MD., et al.

A study was conducted of 30 volunteer patients clinically diagnosed with rheumatoid arthritis. A sample of synovial fluid was taken from each of them at commencement of treatment and after six months of oral and IM treatment with Rhemacell (sulfurylase, sulfokinase and choline acetylase).

Results: Out of the 30 patients, 24 (80%) experienced a clinical improvement of their symptoms, both as regards morning stiffness and arthritis in their hand joints. PMN counts decreased in 27 patients (90%), of the sampling.

Monograph >

Bibliography:
Adams, D.O., et al.: Phagocytic cells: Cytotoxic activities of macrophages. In: Gallin J.I., Goldstein, I.M., Snyderman, R. (Eds); Inflammation – Basic principles and clinical correlates. Raven Press, New York, 1989.
Adibi, S.A., Mercer, D.W.: Protein digestion in human intestine as reflected in luminar, mucosal, and plasma amino acid concentration after meals. J. Clin. Invest. 52:1586-1594 (1973).
Ambarse, A.M.; De Eds, F.: Effects of rutin on permeability of cutaneous capillaries. Pharmacol. Exp. Ther. 90:359 (1989).